Clinical trials: Stage III Lung Non-Small Cell Cancer AJCC v7
NSCLC, Stage III
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
This is a Prospective, open, single arm study to evaluate the efficacy and safety of the almonertinib combined with concurrent chemoradiotherapy in unresectable stage III NSCLC with EGFR mutation
- Trial name
- NCT04952168
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Yuan Chen
Lung Cancer
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00526890
- Testing
- selenomethionine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
CLEAR-Lung III: Circulating Tumor DNA-Guided Consolidation Chemotherapy and Immunotherapy
CLEAR LUNG-III is a single-arm, phase II study evaluating a circulating tumor DNA (ctDNA)-guided treatment strategy in patients with unresectable stage III non-small cell lung cancer who have completed definitive chemoradiation…
- Trial name
- NCT07858253
- Testing
- Consolidation Chemotherapy
- Volunteers
- 43 people
- Sponsor
- Anusha Chidharla, MD
Non-small-cell Lung Cancer (NSCLC)
A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients
This large multinational, non-interventional study (NIS), will retrospectively collect data derived from established medical records over a period of up to approximately 6 years (2013 to 2018), building a platform to capture and…
- Trial name
- KINDLE (NCT03725475)
- Where
- 32 sites in Argentina, Chile and 8 more
- Volunteers
- 3,111 people
- Sponsor
- AstraZeneca
Lung Cancer
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy given after standard therapy to see how well it works in treating patients with stage…
- Trial name
- NCT00019929
- Testing
- mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00310154
- Testing
- docetaxel, gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00023673
- Testing
- carboplatin, paclitaxel, three-dimensional conformal radiation therapy
- Where
- 41 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer, Neurotoxicity
Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells.
- Conditions
- Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00003072
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of California, San Francisco
Small Cell Lung Cancer (SCLC)
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
This is a non-interventional, observational, multicentre, one-arm, non-comparative, and retrospective study. The study is based on the collection of data about the patients treated with Durvalumab after chemoraditherapy in the…
- Trial name
- S-REAL (NCT04285866)
- Testing
- Durvalumab
- Where
- 39 sites in Spain
- Volunteers
- 245 people
- Sponsor
- Fundación GECP
Non Small Cell Lung Cancer
131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)
The aim of this feasibility study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with radiochemotherapy, for the treatment of patients with newly diagnosed…
- Trial name
- NCT01124812
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Philogen S.p.A.
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage…
- Conditions
- Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer, EGFR Mutation-Related Tumors
- Trial name
- NCT04304638
- Testing
- radiation or chemo-radiation, EGFR-TKI Inhibitor
- Volunteers
- 450 people
- Sponsor
- Chinese Academy of Medical Sciences
Carcinoma, Non-Small-Cell Lung
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA…
- Trial name
- NCT02343952
- Testing
- Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 93 people
- Sponsor
- Nasser Hanna, M.D.
Non-Small Cell Lung Cancer
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and…
- Trial name
- NCT00787852
- Testing
- Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47, Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Non-Small Cell Lung Cancer
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
Pemetrexed is approved for second line therapy in metastatic NSCLC. Given the single-agent activity of pemetrexed and the tolerability of pemetrexed in combination with radiation, this study will evaluate survival rates and…
- Trial name
- NCT00732303
- Testing
- Pemetrexed, Radiation Therapy
- Where
- 18 sites in United States
- Volunteers
- 8 people
- Sponsor
- Hoosier Cancer Research Network
Stage III Non-small Cell Lung Cancer
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus…
- Trial name
- NCT05468242
- Testing
- Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung
Stage III NSCLC RWE in Chinese Patients
The objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in Chinese patients with treatment-naïve stage III non-small cell lung cancer (NSCLC) in real world setting.
- Trial name
- NCT04023812
- Where
- 25 sites in China
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
This is an open label, multi-institutional, single arm Phase II trial. All patients will be treated with Carboplatin, Paclitaxel, Durvalumab and Radiation.
- Trial name
- NCT03871153
- Testing
- Durvalumab, Paclitaxel, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Greg Durm, MD
Pulmonary Hypertension
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
In the radiotherapeutic treatment of lung cancer, the dose that can be safely applied to the tumour is limited by the risk of radiation induced lung damage. This damage is characterized by parenchymal damage and vascular damage.
- Trial name
- MRI-HART (NCT02377934)
- Testing
- Cardiac Magnetic Resonance Imaging (MRI)
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- University Medical Center Groningen
Head and Neck Cancer, Lung Cancer
Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
RATIONALE: Fluorescent bronchoscopy, when used in combination with conventional white light bronchoscopy, may improve the ability to detect early lung cancer.
- Trial name
- NCT00019201
- Testing
- cytology specimen collection procedure, immunohistochemistry staining method, sputum cytology
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Immunotherapy, Intensity Modulated Radiation Therapy
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Simultaneous radiotherapy followed by adjuvant immunotherapy is the standard treatment modality of unresectable stage III NSCLC.
- Conditions
- Immunotherapy, Intensity Modulated Radiation Therapy, Radiotherapy, NSCLC
- Trial name
- NCT05909137
- Testing
- IMRT+adjuvant immunotherapy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xinqiao Hospital of Chongqing